Six patients in the CAM2029 arm and 1 patient in the placebo arm had protocol deviations whereby >35 days elapsed between the last treatment dose and the final sample being taken for IGF-1 measurement; 3 of these were due to COVID-19-related disruptions. This evidence concerns the gene IGF1 and COVID-19.